ECSP12012092A - Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleuquina-6 (il-6r) - Google Patents
Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleuquina-6 (il-6r)Info
- Publication number
- ECSP12012092A ECSP12012092A ECSP12012092A ECSP12012092A EC SP12012092 A ECSP12012092 A EC SP12012092A EC SP12012092 A ECSP12012092 A EC SP12012092A EC SP12012092 A ECSP12012092 A EC SP12012092A
- Authority
- EC
- Ecuador
- Prior art keywords
- interleuquina
- formulations containing
- containing anti
- stabilized formulations
- antibody
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
- A61J1/06—Ampoules or carpules
- A61J1/065—Rigid ampoules, e.g. glass ampoules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/248—IL-6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invención proporciona formulaciones farmacéuticas que comprenden un anticuerpo humano que se une de modo específico al receptor de interleuquina-6 humana (hIL-6R). Las formulaciones pueden contener, además de un anticuerpo anti-hIL-6R, al menos un aminoácidos, al menos un azúcar y/o al menos un tensioactivo no iónico. Las formulaciones farmacéuticas de la presente invención muestran un grado sustancial de estabilidad del anticuerpo después de una conservación durante varios meses.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29322710P | 2010-01-08 | 2010-01-08 | |
| US12/986,223 US9173880B2 (en) | 2010-01-08 | 2011-01-07 | Stabilized formulations containing anti-interleukin-6 receptor (IL-6R) antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP12012092A true ECSP12012092A (es) | 2012-09-28 |
Family
ID=44258720
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSP12012092 ECSP12012092A (es) | 2010-01-08 | 2012-08-07 | Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleuquina-6 (il-6r) |
Country Status (43)
Families Citing this family (116)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| US20130064834A1 (en) | 2008-12-15 | 2013-03-14 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to pcsk9 |
| JO3417B1 (ar) | 2010-01-08 | 2019-10-20 | Regeneron Pharma | الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r |
| PL2616090T3 (pl) | 2010-09-17 | 2023-12-18 | Takeda Pharmaceutical Company Limited | Stabilizowanie immunoglobulin poprzez wodną formulację z histydyną o ph od słabo kwaśnego do obojętnego |
| MX366337B (es) | 2010-10-06 | 2019-07-05 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleucina-4 (il-4r). |
| CA2825778A1 (en) | 2011-01-28 | 2012-08-02 | Sanofi | Pharmaceutical compositions comprising human antibodies to pcsk9 |
| AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| ES2773111T3 (es) | 2011-09-16 | 2020-07-09 | Regeneron Pharma | Inhibidor de la proproteína convertasa subtilisina/kexina 9 (PCSK9) para su uso en la reducción de los niveles de lipoproteína (a) |
| TWI589299B (zh) * | 2011-10-11 | 2017-07-01 | 再生元醫藥公司 | 用於治療類風濕性關節炎之組成物及其使用方法 |
| US9943594B2 (en) | 2011-10-11 | 2018-04-17 | Sanofi Biotechnology | Methods for the treatment of rheumatoid arthritis |
| KR20200039028A (ko) * | 2011-10-11 | 2020-04-14 | 사노피 바이오테크놀로지, 소시에떼 빠르 악씨옹 셍쁠리피에 | 류마티스 관절염 치료를 위한 조성물 및 이의 이용방법 |
| JO3370B1 (ar) * | 2011-11-10 | 2019-03-13 | Regeneron Pharma | طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6 |
| AU2012340107B2 (en) | 2011-11-18 | 2017-06-15 | Regeneron Pharmaceuticals, Inc. | Polymer protein microparticles |
| KR102063028B1 (ko) * | 2012-01-23 | 2020-01-07 | 리제너론 파아마슈티컬스, 인크. | 항-ang2 항체를 함유하는 안정화된 제형 |
| US9592289B2 (en) | 2012-03-26 | 2017-03-14 | Sanofi | Stable IgG4 based binding agent formulations |
| PT2830658T (pt) * | 2012-03-26 | 2018-12-28 | Sanofi Sa | Formulações de agente de ligação igg4 estável |
| US20150239970A1 (en) * | 2012-10-25 | 2015-08-27 | Medimmune, Llc | Stable, Low Viscosity Antibody Formulation |
| KR102149206B1 (ko) | 2012-11-08 | 2020-08-31 | 세센 바이오, 아이엔씨. | 인터루킨-6의 길항제 및 이의 용도 |
| AR095196A1 (es) | 2013-03-15 | 2015-09-30 | Regeneron Pharma | Medio de cultivo celular libre de suero |
| US10111953B2 (en) | 2013-05-30 | 2018-10-30 | Regeneron Pharmaceuticals, Inc. | Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9) |
| TW201534324A (zh) | 2013-06-07 | 2015-09-16 | Sanofi Sa | 藉由投與pcsk9抑制劑抑制動脈粥狀硬化的方法 |
| US10428157B2 (en) | 2013-11-12 | 2019-10-01 | Sanofi Biotechnology | Dosing regimens for use with PCSK9 inhibitors |
| DE202014010499U1 (de) | 2013-12-17 | 2015-10-20 | Kymab Limited | Targeting von humaner PCSK9 zur Cholesterinbehandlung |
| US9017678B1 (en) | 2014-07-15 | 2015-04-28 | Kymab Limited | Method of treating rheumatoid arthritis using antibody to IL6R |
| WO2015116852A1 (en) | 2014-01-29 | 2015-08-06 | Regeneron Pharmaceuticals, Inc. | Methods for treating rheumatoid arthritis by administering an il-6r antibody |
| KR20230074283A (ko) | 2014-07-16 | 2023-05-26 | 사노피 바이오테크놀로지 | 이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법 |
| SI3215530T1 (sl) | 2014-11-07 | 2020-02-28 | Sesen Bio, Inc. | Izboljšana protitelesa IL-6 |
| CN112545886A (zh) | 2015-03-10 | 2021-03-26 | 里珍纳龙药品有限公司 | 无菌刺穿系统和方法 |
| AR104847A1 (es) * | 2015-06-17 | 2017-08-16 | Lilly Co Eli | Formulación de anticuerpo anti-cgrp |
| TW202440903A (zh) | 2015-08-04 | 2024-10-16 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法(一) |
| EA201890519A1 (ru) | 2015-08-18 | 2018-07-31 | Ридженерон Фармасьютикалз, Инк. | Ингибирующие антитела против pcsk9 для лечения пациентов с гиперлипидемией, подвергающихся аферезу липопротеинов |
| BR112018017031A2 (pt) | 2016-02-23 | 2019-01-22 | Sesen Bio Inc | formulações de antagonista de il-6 e usos das mesmas |
| KR20230093522A (ko) * | 2016-03-07 | 2023-06-27 | 사노피 바이오테크놀로지 | 류마티스 관절염의 치료를 위한 조성물 및 방법 |
| EP3216461A1 (en) | 2016-03-07 | 2017-09-13 | Sanofi Biotechnology | Compositions and methods for treating rheumatoid arthritis |
| WO2018039499A1 (en) | 2016-08-24 | 2018-03-01 | Regeneron Pharmaceuticals, Inc. | Host cell protein modification |
| BR112019005328A2 (pt) | 2016-09-27 | 2019-06-18 | Fresenius Kabi Deutschland Gmbh | composição farmacêutica líquida |
| US11249082B2 (en) | 2016-10-29 | 2022-02-15 | University Of Miami | Zika virus assay systems |
| WO2018081755A1 (en) * | 2016-10-29 | 2018-05-03 | University Of Miami | Zika virus antibodies |
| BR112019006853B1 (pt) | 2016-10-31 | 2021-08-24 | Fresenius Kabi Deutschland Gmbh | Composição farmacêutica líquida, seu método de fabricação, seu uso, kit e dispositivo de liberação de fármaco que a compreendem e método de fabricação do dito dispositivo |
| BR112019011900A2 (pt) * | 2016-12-23 | 2019-11-26 | Serum Institute Of India Private Limited | métodos melhorados para aumentar a produtividade de anticorpos na cultura de células de mamíferos e minimizar a agregação durante os processos downs-tream, processos de formulação, e formulações de anticorpos estáveis obtidas dos mesmos |
| JP7630906B2 (ja) | 2017-02-01 | 2025-02-18 | イェール・ユニヴァーシティー | 利尿薬耐性の治療 |
| CA3055583A1 (en) | 2017-05-05 | 2018-11-08 | Regeneron Pharmaceuticals, Inc. | Auto-injector |
| KR20210084695A (ko) | 2017-07-06 | 2021-07-07 | 리제너론 파마슈티칼스 인코포레이티드 | 당단백질을 만들기 위한 세포 배양 과정 |
| MX2020005630A (es) * | 2017-11-30 | 2020-08-20 | Bio Thera Solutions Ltd | Formulacion liquida de anticuerpos humanizados para el tratamiento de enfermedades relacionadas con il-6. |
| US20190194298A1 (en) | 2017-12-22 | 2019-06-27 | Regeneron Pharmaceuticals, Inc. | System and method for characterizing drug product impurities |
| SG11202006157VA (en) | 2018-01-05 | 2020-07-29 | Corvidia Therapeutics Inc | Methods for treating il-6 mediated inflammation without immunosuppression |
| CA3085177A1 (en) | 2018-01-31 | 2019-08-08 | Regeneron Pharamaceuticals, Inc. | System and method for characterizing size and charge variant drug product impurities |
| TW202311746A (zh) | 2018-02-02 | 2023-03-16 | 美商再生元醫藥公司 | 用於表徵蛋白質二聚合之系統及方法 |
| AU2019227531B2 (en) | 2018-02-28 | 2025-01-30 | Regeneron Pharmaceuticals, Inc. | Systems and methods for identifying viral contaminants |
| US12259355B2 (en) | 2018-03-19 | 2025-03-25 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| US11054389B2 (en) | 2018-03-19 | 2021-07-06 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| US12253490B2 (en) | 2018-03-19 | 2025-03-18 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| TW202016125A (zh) | 2018-05-10 | 2020-05-01 | 美商再生元醫藥公司 | 用於定量及調節蛋白質黏度之系統與方法 |
| US11830582B2 (en) | 2018-06-14 | 2023-11-28 | University Of Miami | Methods of designing novel antibody mimetics for use in detecting antigens and as therapeutic agents |
| MY204234A (en) | 2018-08-27 | 2024-08-16 | Regeneron Pharma | Use of raman spectroscopy in downstream purification |
| KR20260109977A (ko) | 2018-08-29 | 2026-07-13 | 리제너론 파아마슈티컬스, 인크. | 류마티스성 관절염을 갖는 대상체를 치료하기 위한 방법 및 조성물 |
| WO2020047067A1 (en) | 2018-08-30 | 2020-03-05 | Regeneron Pharmaceuticals, Inc. | Methods for characterizing protein complexes |
| WO2020088346A1 (en) * | 2018-10-31 | 2020-05-07 | Mycenax Biotech Inc. | Aqueous pharmaceutical formulations |
| JP2022517720A (ja) | 2019-01-16 | 2022-03-10 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ジスルフィド結合を特徴付けるための方法 |
| JP7542543B2 (ja) | 2019-01-31 | 2024-08-30 | サノフィ・バイオテクノロジー | 若年性特発性関節炎を治療するための抗il-6受容体抗体 |
| PE20212185A1 (es) | 2019-02-18 | 2021-11-11 | Lilly Co Eli | Formulacion de anticuerpos terapeuticos |
| JP2022545312A (ja) | 2019-04-24 | 2022-10-27 | サノフィ・バイオテクノロジー | 関節リウマチの診断及び処置の方法 |
| JP7541534B2 (ja) | 2019-05-13 | 2024-08-28 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 改善された競合的リガンド結合アッセイ |
| CA3142710A1 (en) | 2019-06-04 | 2020-12-10 | Sanofi Biotechnology | Compositions and methods for treating pain in subjects with rheumatoid arthritis |
| CN114375205A (zh) | 2019-06-20 | 2022-04-19 | 武田药品工业株式会社 | 用基于病毒的基因疗法进行治疗的方法 |
| KR20260058863A (ko) | 2019-09-24 | 2026-04-29 | 리제너론 파아마슈티컬스, 인크. | 크로마토그래피의 사용 및 재생을 위한 시스템 및 방법 |
| US12297451B1 (en) | 2019-10-25 | 2025-05-13 | Regeneron Pharmaceuticals, Inc. | Cell culture medium |
| US11730793B2 (en) | 2019-11-25 | 2023-08-22 | Regeneron Pharmaceuticals, Inc. | Sustained release formulations using non-aqueous emulsions |
| CA3165060C (en) | 2020-01-21 | 2023-06-20 | Yiming Zhao | Deglycosylation methods for electrophoresis of glycosylated proteins |
| WO2021163549A1 (en) | 2020-02-14 | 2021-08-19 | Sanofi Biotechnology | Compositions and methods for treating viral infections |
| CA3180369A1 (en) | 2020-05-26 | 2021-12-02 | Inka Albrecht | Compositions comprising an antibody against interleukin-6 receptor for the treatment of rheumatoid arthritis and methods of using same |
| US20230192871A1 (en) | 2020-05-29 | 2023-06-22 | Sanofi Biotechnology | Compositions and methods for treating noninflammatory pain in subjects with rheumatoid arthritis |
| CA3185091A1 (en) * | 2020-07-08 | 2022-01-13 | Yuan Cheng | Stabilized formulations containing anti-ctla-4 antibodies |
| KR20230058094A (ko) | 2020-08-31 | 2023-05-02 | 리제너론 파아마슈티컬스, 인크. | 세포 배양 성능을 개선하고 아스파라긴 서열 변이체를 완화하기 위한 아스파라긴 공급 전략 |
| KR20220028972A (ko) * | 2020-08-31 | 2022-03-08 | (주)셀트리온 | 안정한 약제학적 제제 |
| WO2022102768A1 (ja) * | 2020-11-16 | 2022-05-19 | アステラス製薬株式会社 | 抗tspan8-抗cd3二重特異性抗体及び抗tspan8抗体 |
| EP4251128A1 (en) | 2020-11-25 | 2023-10-04 | Regeneron Pharmaceuticals, Inc. | Sustained release formulations using non-aqueous membrane emulsification |
| IL303675A (en) | 2020-12-17 | 2023-08-01 | Regeneron Pharma | Production of protein thermal microgels |
| MX2023008527A (es) | 2021-01-20 | 2023-07-28 | Regeneron Pharma | Metodos para mejorar el valor proteico en cultivo celular. |
| TW202246325A (zh) | 2021-03-03 | 2022-12-01 | 美商再生元醫藥公司 | 用於定量及修飾蛋白質黏度之系統及方法 |
| EP4315344A1 (en) | 2021-03-26 | 2024-02-07 | Regeneron Pharmaceuticals, Inc. | Methods and systems for developing mixing protocols |
| AU2022286340A1 (en) | 2021-06-01 | 2024-01-04 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| WO2023020563A1 (en) * | 2021-08-18 | 2023-02-23 | Bio-Thera Solutions, Ltd. | Liquid formulations comprising high concentrations humanized antibodies for treating il-6 related diseases |
| AR127006A1 (es) | 2021-09-08 | 2023-12-06 | Regeneron Pharma | UN MÉTODO BASADO EN ESPECTROMETRÍA DE MASAS Y DE ALTO RENDIMIENTO PARA CUANTIFICAR ANTICUERPOS Y OTRAS PROTEÍNAS QUE CONTIENEN Fc |
| AU2022348521A1 (en) | 2021-09-20 | 2024-04-04 | Regeneron Pharmaceuticals, Inc. | Methods of controlling antibody heterogeneity |
| EP4413364A2 (en) | 2021-10-07 | 2024-08-14 | Regeneron Pharmaceuticals, Inc. | Systems and methods of ph modeling and control |
| EP4413359A1 (en) | 2021-10-07 | 2024-08-14 | Regeneron Pharmaceuticals, Inc. | Ph meter calibration and correction |
| WO2023076340A1 (en) | 2021-10-26 | 2023-05-04 | Regeneron Pharmaceuticals, Inc. | Systems and methods for generating laboratory water and distributing laboratory water at different temperatures |
| USD1007676S1 (en) | 2021-11-16 | 2023-12-12 | Regeneron Pharmaceuticals, Inc. | Wearable autoinjector |
| EP4493921A1 (en) | 2022-03-18 | 2025-01-22 | Regeneron Pharmaceuticals, Inc. | Methods and systems for analyzing polypeptide variants |
| EP4634659A1 (en) | 2022-12-16 | 2025-10-22 | Regeneron Pharmaceuticals, Inc. | Methods and systems for assessing chromatographic column integrity |
| US20240248097A1 (en) | 2023-01-25 | 2024-07-25 | Regeneron Pharmaceuticals, Inc. | Mass spectrometry-based characterization of antibodies co-expressed in vivo |
| US20240245779A1 (en) | 2023-01-25 | 2024-07-25 | Regeneron Pharmaceuticals, Inc. | Methods of modeling liquid protein composition stability |
| TW202445138A (zh) | 2023-02-01 | 2024-11-16 | 美商再生元醫藥公司 | 用於生物巨分子分析之具質譜法的不對稱流場流分離 |
| EP4669963A2 (en) | 2023-02-22 | 2025-12-31 | Regeneron Pharmaceuticals, Inc. | SYSTEM FITNESS PARAMETERS AND COLUMN AGING |
| JP2026514305A (ja) | 2023-05-01 | 2026-05-08 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | フェノールまたはベンジルアルコールを使用した複数回投与抗体医薬品 |
| WO2024259313A1 (en) | 2023-06-16 | 2024-12-19 | Regeneron Pharamceuticals, Inc. | Medical device packaging and related methods |
| US20250086164A1 (en) | 2023-09-08 | 2025-03-13 | Regeneron Pharmaceuticals, Inc. | Methods and systems for assessing chromatographic column integrity |
| EP4780828A2 (en) | 2023-09-18 | 2026-07-29 | Regeneron Pharmaceuticals, Inc. | Methods and systems for developing chromatography protocols |
| US20250109905A1 (en) | 2023-09-29 | 2025-04-03 | Regeneron Pharmaceuticals, Inc. | Lyophilization using controlled nucleation |
| TW202529831A (zh) | 2023-10-02 | 2025-08-01 | 美商再生元醫藥公司 | 藥物遞輸裝置安全系統 |
| CN122138969A (zh) | 2023-10-18 | 2026-06-02 | 瑞泽恩制药公司 | 从过程中上游细胞培养物材料中快速纯化单克隆抗体 |
| AU2024373307A1 (en) | 2023-11-02 | 2026-05-14 | Regeneron Pharmaceuticals, Inc. | Methods for reducing lipase activity using stress |
| TW202547482A (zh) | 2024-01-12 | 2025-12-16 | 法商賽諾菲生物技術公司 | 已接受類固醇之具有風濕性多肌痛症之個體之治療 |
| WO2025166281A1 (en) | 2024-02-01 | 2025-08-07 | Regeneron Pharmaceuticals, Inc. | Platform for charge-detection mass spectrometry analysis of aavs |
| TW202600593A (zh) | 2024-02-16 | 2026-01-01 | 美商再生元醫藥公司 | 製造濃縮配製包括蛋白質之藥品物質之方法,以及該方法製造之濃縮配製之藥品物質 |
| TW202602489A (zh) | 2024-03-15 | 2026-01-16 | 美商再生元醫藥公司 | 作為經穩定的蛋白質調配物之賦形劑的聚山梨醇酯及聚氧乙烯山梨糖醇酐 |
| WO2025259840A1 (en) | 2024-06-13 | 2025-12-18 | Regeneron Pharmaceuticals, Inc. | Methods and systems for scaled chromatography |
| TW202617180A (zh) * | 2024-06-20 | 2026-05-01 | 南韓商賽特瑞恩股份有限公司 | 穩定的藥學製劑 |
| WO2026025028A1 (en) | 2024-07-26 | 2026-01-29 | Regeneron Pharmaceuticals, Inc. | Methods of making ultra-high concentrated protein formulations using lyophilization |
| WO2026060350A1 (en) | 2024-09-13 | 2026-03-19 | Regeneron Pharmaceuticals, Inc. | Methods of improving photo stability and controlling formation of hmw species in biologic formulations, and biologic formulations produced by the methods |
| WO2026076201A2 (en) | 2024-10-03 | 2026-04-09 | Regeneron Pharmaceuticals, Inc. | Systems and methods for producing therapeutic proteins using single pass tangential flow filtration for in-line concentration and volume reduction of production pools |
| WO2026080597A1 (en) | 2024-10-08 | 2026-04-16 | Regeneron Pharmaceuticals, Inc. | Sustained delivery of biologics and non-aqueous manufacture of same |
| WO2026112457A2 (en) | 2024-11-21 | 2026-05-28 | Regeneron Pharmaceuticals, Inc. | Heterodimeric antigen-binding molecules that bind to viral particles and uses thereof |
| WO2026136650A1 (en) | 2024-12-20 | 2026-06-25 | Regeneron Pharmaceuticals, Inc. | Fixed seed train schedule for improved protein production |
| US20260221053A1 (en) | 2025-01-29 | 2026-07-30 | Regeneron Pharmaceuticals, Inc. | Drug delivery devices, safety systems, training devices, and methods of use thereof |
Family Cites Families (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1007208A (en) | 1911-07-21 | 1911-10-31 | Axel W Johnson | Window. |
| JPH0747045B2 (ja) | 1986-10-15 | 1995-05-24 | 株式会社大協精工 | 積層した注射器用滑栓 |
| US5171840A (en) | 1988-01-22 | 1992-12-15 | Tadamitsu Kishimoto | Receptor protein for human B cell stimulatory factor-2 |
| US5670373A (en) | 1988-01-22 | 1997-09-23 | Kishimoto; Tadamitsu | Antibody to human interleukin-6 receptor |
| US5216128A (en) | 1989-06-01 | 1993-06-01 | Yeda Research And Development Co., Ltd. | IFN-β2/IL-6 receptor its preparation and pharmaceutical compositions containing it |
| SG42954A1 (en) | 1989-07-20 | 1997-10-17 | Tadamitsu Kishimoto | Antibody to human interleukin-6 receptor |
| US5605690A (en) | 1989-09-05 | 1997-02-25 | Immunex Corporation | Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5016784A (en) * | 1990-02-15 | 1991-05-21 | Dexus Research Inc. | Applicator for highly reactive materials |
| DE07012626T1 (de) | 1991-03-18 | 2010-01-21 | New York University | Monoklonale und chimäre Antikörper gegen humanen Tumornekrosefaktor |
| AU668349B2 (en) | 1991-04-25 | 1996-05-02 | Chugai Seiyaku Kabushiki Kaisha | Reconstituted human antibody against human interleukin 6 receptor |
| JP3100727B2 (ja) | 1992-01-23 | 2000-10-23 | 株式会社大協精工 | 変性ポリシロキサン組成物及び該組成物を被覆した衛生ゴム製品 |
| FR2694767B1 (fr) | 1992-08-13 | 1994-10-21 | Innotherapie Lab Sa | Anticorps monoclonaux anti-IL6R, et leurs applications. |
| NZ256293A (en) | 1992-09-15 | 1997-06-24 | Immunex Corp | Method of treating tumour necrosis factor - mediated inflammation by use of tnf antagonist |
| AU687763B2 (en) | 1992-10-20 | 1998-03-05 | Central Laboratory Of The Netherlands Red Cross Blood Transfusion Service | Interleukin-6 receptor antagonists |
| US5888511A (en) | 1993-02-26 | 1999-03-30 | Advanced Biotherapy Concepts, Inc. | Treatment of autoimmune diseases, including AIDS |
| US5888510A (en) | 1993-07-21 | 1999-03-30 | Chugai Seiyaku Kabushiki Kaisha | Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component |
| WO1995009873A1 (en) | 1993-10-06 | 1995-04-13 | Board Of Regents, The University Of Texas System | A monoclonal anti-human il-6 receptor antibody |
| AU700819B2 (en) | 1994-10-07 | 1999-01-14 | Chugai Seiyaku Kabushiki Kaisha | Rheumatoid arthritis remedy containing IL-6 antagonist as effective component |
| PL182089B1 (en) | 1994-10-21 | 2001-11-30 | Chugai Pharmaceutical Co Ltd | Pharmaceutic compositions for treating diseases caused by production of il-6 |
| US6086874A (en) | 1994-12-29 | 2000-07-11 | Chugai Seiyaku Kabushiki Kaisha | Antitumor agent effect enhancer containing IL-6 antagonist |
| US6261560B1 (en) | 1995-02-13 | 2001-07-17 | Chugai Seiyaku Kabushiki Kaisha | Method for inhibiting muscle protein proteolysis with antibodies to interleukin-6 receptor |
| JP3172057B2 (ja) | 1995-04-05 | 2001-06-04 | 株式会社大協精工 | ラミネートゴム栓 |
| ZA971600B (en) | 1996-02-26 | 1997-09-22 | Merck & Co Inc | Treatment of macular edema. |
| DK0923941T3 (da) | 1996-06-27 | 2006-09-18 | Chugai Pharmaceutical Co Ltd | Midler mod myelom der skal anvendes sammen med nitrogensennepantitumormidler |
| US5795695A (en) | 1996-09-30 | 1998-08-18 | Xerox Corporation | Recording and backing sheets containing linear and cross-linked polyester resins |
| US7312196B2 (en) | 1997-01-08 | 2007-12-25 | Amylin Pharmaceuticals, Inc. | Formulations for amylin agonist peptides |
| KR20040024561A (ko) | 1997-08-15 | 2004-03-20 | 츄가이 세이야꾸 가부시키가이샤 | 항 인터루킨-6 수용체 항체를 유효성분으로서 함유하는전신성 홍반성 낭창의 예방 및/또는 치료제 |
| US20020187150A1 (en) | 1997-08-15 | 2002-12-12 | Chugai Seiyaku Kabushiki Kaisha | Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-IL-6 receptor antibody as an active ingredient |
| ATE383875T1 (de) | 1998-03-17 | 2008-02-15 | Chugai Pharmaceutical Co Ltd | Prophylaktische oder therapeutische mittel gegen entzündliche erkrankungen des verdauungstraktes enthaltend antagonistische il-6 rezeptor antikörper |
| CA2341239C (en) | 1998-08-24 | 2011-01-04 | Chugai Seiyaku Kabushiki Kaisha | A preventive or therapeutic agent for pancreatitis comprising il-6 antagonist as an active ingredient |
| JP3512349B2 (ja) | 1999-01-29 | 2004-03-29 | 株式会社大協精工 | 柱状ゴム要素の成形型 |
| EP1224189B1 (en) | 1999-10-07 | 2006-01-25 | Eli Lilly And Company | Condensed dihydroquinolinone derivatives for inhibiting mrp1 |
| US6629949B1 (en) | 2000-05-08 | 2003-10-07 | Sterling Medivations, Inc. | Micro infusion drug delivery device |
| US6659982B2 (en) | 2000-05-08 | 2003-12-09 | Sterling Medivations, Inc. | Micro infusion drug delivery device |
| US8632778B2 (en) * | 2000-08-11 | 2014-01-21 | Chugai Seiyaku Kabushiki Kaisha | Stabilized anti-interleukin-6 antibody-containing preparations |
| US7148197B2 (en) | 2000-08-24 | 2006-12-12 | The Regents Of The University Of California | Orally administered small peptides synergize statin activity |
| EP1327681A4 (en) | 2000-10-20 | 2004-09-01 | Chugai Pharmaceutical Co Ltd | Degraded agonist antibodies |
| AU1095202A (en) | 2000-10-25 | 2002-05-06 | Chugai Pharmaceutical Co Ltd | Preventives or remedies for psoriasis containing as the active ingredient il-6 antagonist |
| JP4889187B2 (ja) | 2000-10-27 | 2012-03-07 | 中外製薬株式会社 | Il−6アンタゴニストを有効成分として含有する血中mmp−3濃度低下剤 |
| JP2002209975A (ja) | 2001-01-19 | 2002-07-30 | Daikyo Seiko Ltd | 医薬バイアル用ラミネートゴム栓 |
| UA80091C2 (en) | 2001-04-02 | 2007-08-27 | Chugai Pharmaceutical Co Ltd | Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist |
| CA2817619A1 (en) | 2001-06-08 | 2002-12-08 | Abbott Laboratories (Bermuda) Ltd. | Methods of administering anti-tnf.alpha. antibodies |
| ATE454137T1 (de) | 2001-07-25 | 2010-01-15 | Facet Biotech Corp | Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab |
| BRPI0214168B8 (pt) | 2001-11-14 | 2021-05-25 | Centocor Inc | anticorpos anti-il-6, moléculas de ácido nucleico codificando os mesmos, vetores compreendendo as referidas moléculas, composições e formulações compreendendo os referidos anticorpos, bem como métodos de produção dos mesmos |
| WO2003068260A1 (fr) | 2002-02-14 | 2003-08-21 | Chugai Seiyaku Kabushiki Kaisha | Produits pharmaceutiques en solution contenant des anticorps |
| US20060078532A1 (en) | 2004-10-12 | 2006-04-13 | Omoigui Osemwota S | Method of prevention and treatment of Atherosclerosis, Peripheral vascular disease, Coronary artery disease, aging and age-related disorders including osteoporosis, arthritis, type 2 diabetes, dementia and Alzheimer's disease |
| US20060078531A1 (en) | 2004-10-12 | 2006-04-13 | Osemwota Sota | Method of prevention and treatment of atherosclerosis, peripheral vascular disease, coronary artery disease, and age-related disorders including osteoporosis, arthritis, type 2 diabetes, dementia and Alzheimer's disease |
| US20060275294A1 (en) | 2002-08-22 | 2006-12-07 | Omoigui Osemwota S | Method of prevention and treatment of aging, age-related disorders and/or age-related manifestations including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimers disease and cancer |
| US20060078533A1 (en) | 2004-10-12 | 2006-04-13 | Omoigui Osemwota S | Method of prevention and treatment of aging and age-related disorders including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimer's disease and cancer |
| US7534427B2 (en) | 2002-12-31 | 2009-05-19 | Immunomedics, Inc. | Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins |
| PT1610820E (pt) | 2003-04-04 | 2010-12-16 | Novartis Ag | Formulações de elevada concentração de anticorpos e proteínas |
| ME00426B (me) | 2003-04-09 | 2011-10-10 | Genentech Inc | Liječenje autoimunih bolesti kod pacijenata sa neadekvatnim odgovorom na tnf-alfa inhibitor |
| GB2401040A (en) | 2003-04-28 | 2004-11-03 | Chugai Pharmaceutical Co Ltd | Method for treating interleukin-6 related diseases |
| CA2539061A1 (en) | 2003-09-22 | 2005-03-31 | Biovation Gmbh & Co. Kg | Use of an antagonist of il-6 for treating il-6-mediated diseases |
| DE10355251A1 (de) | 2003-11-26 | 2005-06-23 | Merck Patent Gmbh | Pharmazeutische Zubereitung enthaltend einen Antikörper gegen den EGF-Rezeptor |
| AR048210A1 (es) | 2003-12-19 | 2006-04-12 | Chugai Pharmaceutical Co Ltd | Un agente preventivo para la vasculitis. |
| CA2555688C (en) | 2004-02-11 | 2011-11-08 | Warner-Lambert Company Llc | Methods of treating osteoarthritis with anti-il-6 or anti-il6 receptor antibodies |
| AU2005247341B2 (en) | 2004-05-06 | 2008-05-08 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Methods and compositions for the treatment of uveitis |
| AU2005287406B2 (en) | 2004-07-26 | 2011-08-18 | Biogen Ma Inc. | Anti-CD154 antibodies |
| US20070036788A1 (en) | 2004-09-22 | 2007-02-15 | Ahmed Sheriff | Use of a compound for reducing the biological effectiveness of il-6 |
| JPWO2006046661A1 (ja) | 2004-10-28 | 2008-05-22 | 国立大学法人大阪大学 | インターロイキン−6阻害剤 |
| EP1828250A2 (en) | 2004-12-16 | 2007-09-05 | Genentech, Inc. | Methods for treating autoimmune disorders |
| KR20080071192A (ko) | 2005-11-22 | 2008-08-01 | 와이어쓰 | 면역글로불린 융합 단백질 제형 |
| PL1963368T6 (pl) | 2005-12-13 | 2021-02-08 | Eli Lilly And Company | Przeciwciała anty-IL-17 |
| JP2009525986A (ja) | 2006-02-03 | 2009-07-16 | メディミューン,エルエルシー | タンパク質製剤 |
| US20080131374A1 (en) | 2006-04-19 | 2008-06-05 | Medich John R | Uses and compositions for treatment of rheumatoid arthritis |
| US8080248B2 (en) | 2006-06-02 | 2011-12-20 | Regeneron Pharmaceuticals, Inc. | Method of treating rheumatoid arthritis with an IL-6R antibody |
| ATE537190T1 (de) | 2006-06-02 | 2011-12-15 | Regeneron Pharma | Hochaffine antikörper gegen den humanen il-6- rezeptor |
| JP2009540015A (ja) | 2006-06-14 | 2009-11-19 | イムクローン・リミテッド・ライアビリティ・カンパニー | 抗egfr抗体の凍結乾燥製剤 |
| JP2010500876A (ja) | 2006-08-18 | 2010-01-14 | アブリンクス エン.ヴェー. | Il−6媒介性シグナル伝達に関連する疾患及び障害の治療のための、il−6rに指向性を有するアミノ酸配列及びこれを含むポリペプチド |
| WO2008049897A1 (en) | 2006-10-27 | 2008-05-02 | Ablynx N.V. | Intranasal delivery of polypeptides and proteins |
| AU2008255352B2 (en) | 2007-05-31 | 2014-05-22 | Genmab A/S | Stable IgG4 antibodies |
| RU2505603C2 (ru) | 2007-09-26 | 2014-01-27 | Чугаи Сейяку Кабусики Кайся | Антитело против рецептора il-6 |
| PE20091174A1 (es) | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
| EP2244814B1 (en) | 2007-12-28 | 2021-06-02 | Takeda Pharmaceutical Company Limited | Recombinant vwf formulations |
| WO2009095489A2 (en) | 2008-02-01 | 2009-08-06 | Ablynx N.V. | Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling |
| WO2009109584A1 (en) | 2008-03-07 | 2009-09-11 | Ferring International Center S. A. | ANTIBODY BINDING ONLY TO IL6-sIL6R COMPLEX |
| TW201920257A (zh) | 2008-04-11 | 2019-06-01 | 日商中外製藥股份有限公司 | 重複結合複數個抗原的抗原結合分子 |
| TWI440469B (zh) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
| RU2565809C2 (ru) * | 2009-03-19 | 2015-10-20 | Чугаи Сейяку Кабусики Кайся | Фармацевтический состав, содержащий молекулы антител с улучшенными свойствами |
| JO3030B1 (ar) | 2009-06-26 | 2016-09-05 | Galapagos Nv | مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات |
| JO3417B1 (ar) | 2010-01-08 | 2019-10-20 | Regeneron Pharma | الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r |
| BR112012028557A2 (pt) | 2010-05-07 | 2019-09-24 | Xoma Technology Ltd. | uso de um anticorpo anti-il-1b ou de fragmentos de ligação do mesmo. |
| US9943594B2 (en) | 2011-10-11 | 2018-04-17 | Sanofi Biotechnology | Methods for the treatment of rheumatoid arthritis |
| TWI589299B (zh) | 2011-10-11 | 2017-07-01 | 再生元醫藥公司 | 用於治療類風濕性關節炎之組成物及其使用方法 |
| US20150050277A1 (en) | 2013-03-15 | 2015-02-19 | Aerpio Therapeutics Inc. | Compositions and methods for treating ocular diseases |
| KR20230155586A (ko) | 2013-11-22 | 2023-11-10 | 사노피 바이오테크놀로지 | 류마티스 관절염 치료를 위한 조성물 및 이의 이용방법 |
| IL247942B (en) | 2014-03-27 | 2022-09-01 | Dyax Corp | Compositions and methods for drops in macular edema as a result of diabetes |
| JP7101479B2 (ja) | 2014-09-16 | 2022-07-15 | サノフィ・バイオテクノロジー | 関節リウマチ患者の健康に関連した生活の質を改善するための組成物 |
| BR112018008900A8 (pt) | 2015-11-03 | 2019-02-26 | Regeneron Pharma | composições compreendendo anticorpos para il6r para o tratamento de uveíte e edema macular e métodos de uso das mesmas |
| KR20230093522A (ko) | 2016-03-07 | 2023-06-27 | 사노피 바이오테크놀로지 | 류마티스 관절염의 치료를 위한 조성물 및 방법 |
-
2010
- 2010-12-09 JO JOP/2010/0440A patent/JO3417B1/ar active
-
2011
- 2011-01-05 AR ARP110100021A patent/AR079836A1/es not_active Application Discontinuation
- 2011-01-06 PY PY201101100365A patent/PY1100365A/es unknown
- 2011-01-07 LT LTEP20184418.0T patent/LT3756652T/lt unknown
- 2011-01-07 TW TW104126027A patent/TWI587870B/zh active
- 2011-01-07 SI SI201131915T patent/SI3409269T1/sl unknown
- 2011-01-07 CA CA2790197A patent/CA2790197C/en active Active
- 2011-01-07 HU HUE22172959A patent/HUE073279T2/hu unknown
- 2011-01-07 KR KR1020127020667A patent/KR101787351B1/ko active Active
- 2011-01-07 TW TW100100565A patent/TWI533884B/zh active
- 2011-01-07 PE PE2012000970A patent/PE20121687A1/es active IP Right Grant
- 2011-01-07 PT PT221729593T patent/PT4098247T/pt unknown
- 2011-01-07 PT PT201844180T patent/PT3756652T/pt unknown
- 2011-01-07 PL PL20184418.0T patent/PL3756652T3/pl unknown
- 2011-01-07 HU HUE18174400A patent/HUE051115T2/hu unknown
- 2011-01-07 SM SM20250337T patent/SMT202500337T1/it unknown
- 2011-01-07 HR HRP20221139TT patent/HRP20221139T1/hr unknown
- 2011-01-07 HU HUE11703294A patent/HUE040403T2/hu unknown
- 2011-01-07 PE PE2017000859A patent/PE20170948A1/es unknown
- 2011-01-07 RU RU2012133970/15A patent/RU2554779C2/ru active
- 2011-01-07 PH PH1/2012/501370A patent/PH12012501370B1/en unknown
- 2011-01-07 CN CN201180012860.1A patent/CN102869346B/zh active Active
- 2011-01-07 EP EP25181542.9A patent/EP4588938A3/en active Pending
- 2011-01-07 DK DK11703294.6T patent/DK2521536T3/en active
- 2011-01-07 JP JP2012548134A patent/JP5805660B2/ja active Active
- 2011-01-07 FI FIEP22172959.3T patent/FI4098247T3/fi active
- 2011-01-07 SG SG2012047767A patent/SG182283A1/en unknown
- 2011-01-07 PT PT11703294T patent/PT2521536T/pt unknown
- 2011-01-07 DK DK22172959.3T patent/DK4098247T3/da active
- 2011-01-07 RS RS20181286A patent/RS57903B1/sr unknown
- 2011-01-07 HR HRP20251207TT patent/HRP20251207T1/hr unknown
- 2011-01-07 EP EP20184418.0A patent/EP3756652B1/en active Active
- 2011-01-07 EP EP11703294.6A patent/EP2521536B9/en active Active
- 2011-01-07 UY UY0001033169A patent/UY33169A/es active IP Right Grant
- 2011-01-07 ES ES22172959T patent/ES3040609T3/es active Active
- 2011-01-07 MX MX2012007794A patent/MX2012007794A/es active IP Right Grant
- 2011-01-07 HU HUE20184418A patent/HUE059811T2/hu unknown
- 2011-01-07 LT LTEP11703294.6T patent/LT2521536T/lt unknown
- 2011-01-07 DK DK20184418.0T patent/DK3756652T3/da active
- 2011-01-07 PT PT181744004T patent/PT3409269T/pt unknown
- 2011-01-07 ES ES11703294.6T patent/ES2688070T3/es active Active
- 2011-01-07 WO PCT/US2011/020457 patent/WO2011085158A2/en not_active Ceased
- 2011-01-07 SI SI201132136T patent/SI4098247T1/sl unknown
- 2011-01-07 PL PL22172959.3T patent/PL4098247T3/pl unknown
- 2011-01-07 HR HRP20181821TT patent/HRP20181821T1/hr unknown
- 2011-01-07 NZ NZ601114A patent/NZ601114A/en unknown
- 2011-01-07 SM SM20220365T patent/SMT202200365T1/it unknown
- 2011-01-07 SI SI201131598T patent/SI2521536T1/sl unknown
- 2011-01-07 EP EP22172959.3A patent/EP4098247B1/en active Active
- 2011-01-07 LT LTEP22172959.3T patent/LT4098247T/lt unknown
- 2011-01-07 LT LTEP18174400.4T patent/LT3409269T/lt unknown
- 2011-01-07 ES ES18174400T patent/ES2818992T3/es active Active
- 2011-01-07 RS RS20250944A patent/RS67230B1/sr unknown
- 2011-01-07 RS RS20201334A patent/RS61045B1/sr unknown
- 2011-01-07 SI SI201132064T patent/SI3756652T1/sl unknown
- 2011-01-07 DK DK18174400.4T patent/DK3409269T3/da active
- 2011-01-07 MA MA35130A patent/MA33993B1/fr unknown
- 2011-01-07 SM SM20200577T patent/SMT202000577T1/it unknown
- 2011-01-07 BR BR112012016618-2A patent/BR112012016618A2/pt not_active Application Discontinuation
- 2011-01-07 EP EP18174400.4A patent/EP3409269B1/en active Active
- 2011-01-07 MY MYPI2012002936A patent/MY156702A/en unknown
- 2011-01-07 RS RS20220856A patent/RS63567B1/sr unknown
- 2011-01-07 SM SM20180673T patent/SMT201800673T1/it unknown
- 2011-01-07 US US12/986,223 patent/US9173880B2/en active Active
- 2011-01-07 AU AU2011204311A patent/AU2011204311B2/en active Active
- 2011-01-07 ES ES20184418T patent/ES2925665T3/es active Active
- 2011-01-07 PL PL11703294T patent/PL2521536T3/pl unknown
- 2011-01-07 PL PL18174400T patent/PL3409269T3/pl unknown
- 2011-07-01 UA UAA201209619A patent/UA107211C2/ru unknown
-
2012
- 2012-07-05 ZA ZA2012/05035A patent/ZA201205035B/en unknown
- 2012-07-05 DO DO2012000193A patent/DOP2012000193A/es unknown
- 2012-07-06 NI NI201200119A patent/NI201200119A/es unknown
- 2012-07-06 CL CL2012001853A patent/CL2012001853A1/es unknown
- 2012-07-06 GT GT201200223A patent/GT201200223A/es unknown
- 2012-07-23 CR CR20120393A patent/CR20120393A/es unknown
- 2012-08-07 EC ECSP12012092 patent/ECSP12012092A/es unknown
- 2012-08-08 CO CO12132768A patent/CO6592078A2/es unknown
-
2015
- 2015-09-01 JP JP2015171642A patent/JP6053886B2/ja active Active
- 2015-09-22 US US14/861,565 patent/US10072086B2/en active Active
-
2018
- 2018-08-09 US US16/100,020 patent/US11098127B2/en active Active
- 2018-10-30 CY CY20181101111T patent/CY1121420T1/el unknown
-
2020
- 2020-09-08 HR HRP20201428TT patent/HRP20201428T1/hr unknown
- 2020-11-11 CY CY20201101064T patent/CY1123909T1/el unknown
-
2021
- 2021-04-08 US US17/225,887 patent/US12077593B2/en active Active
-
2024
- 2024-07-23 US US18/781,729 patent/US20250197515A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY33169A (es) | Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleuquina-6 (il-6r) | |
| MX2019008084A (es) | Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleucina-4 (il-4r). | |
| UY33515A (es) | Formulaciones estabilizadas que contienen anticuerpos anti-ngf | |
| CY1122181T1 (el) | Φαρμακοτεχνικη μορφη αντισωματος | |
| CY1126062T1 (el) | Σταθερη φαρμακοτεχνικη μορφη anti-ifnar1 | |
| CO2019011021A2 (es) | Formulacion estable de anticuerpos | |
| MY157772A (en) | Antibody formulation | |
| UY33652A (es) | Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleucina-4(il-ar) | |
| CO2021011648A2 (es) | Formulaciones estabilizadas que contienen anticuerpos anti-il-33 | |
| CO2022008684A2 (es) | Formulaciones estabilizadas que contienen anticuerpos biespecíficos anti-cd20 x anti-cd3 | |
| CY1125584T1 (el) | Σταθεροποιημενα σκευασματα που περιεχουν αντισωματα κατα του υποδοχεα της ιντερλευκινης-6 (il-6r) | |
| TN2012000342A1 (en) | Stabilized formulations containing anti-interleukin-6 receptor (il-6r) antibodies | |
| TH175929A (th) | สูตรตำรับของแอนติบอดี้ (Antibody Formulation) |